
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.

Giada Bianchi, MD, is a physician-scientist and Associate Director of the Amyloidosis Program at Brigham and Women's Hospital/Dana Farber Cancer Institute.

Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.

Giada Bianchi, MD, discusses tailoring therapy in myeloma, addressing ultra-high-risk disease, and amyloidosis becoming a chronic condition at IMS 2026.

October 2nd 2026